News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,127 Results
Type
Article (14914)
Company Profile (58)
Press Release (266154)
Multimedia
Podcasts (82)
Webinars (13)
Section
Business (101856)
Career Advice (494)
Deals (15555)
Drug Delivery (84)
Drug Development (37187)
Employer Resources (55)
FDA (6483)
Job Trends (6349)
News (152088)
Policy (14235)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (463)
Accelerated approval (28)
ADA (11)
Adcomms (10)
Allergies (104)
Alliances (23469)
ALS (76)
Alzheimer's disease (562)
Antibody-drug conjugate (ADC) (191)
Approvals (6838)
Artificial intelligence (307)
ASCO (117)
Autoimmune disease (89)
Automation (22)
Bankruptcy (152)
Best Places to Work (4420)
BIO (24)
BIOSECURE Act (10)
Biosimilars (171)
BioSpace Insights (65)
Biotechnology (27)
Bladder cancer (55)
Brain cancer (42)
Breast cancer (219)
Cancer (1871)
Cardiovascular disease (214)
Career advice (442)
Career pathing (17)
CAR-T (72)
CDC (10)
Cell therapy (222)
Cervical cancer (20)
Clinical research (33065)
Collaboration (1035)
Commercialization (2)
Company closure (1)
Compensation (431)
Complete response letters (51)
COVID-19 (801)
CRISPR (57)
C-suite (723)
Cystic fibrosis (64)
Data (2712)
Decentralized trials (1)
Denatured (19)
Depression (65)
Dermatology (17)
Diabetes (171)
Diagnostics (1495)
Digital health (17)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (189)
Drug pricing (124)
Drug shortages (15)
Duchenne muscular dystrophy (112)
Earnings (34706)
Editorial (28)
Employer branding (6)
Employer resources (51)
Events (40321)
Executive appointments (655)
FDA (8012)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (9)
Funding (603)
Gene editing (92)
Generative AI (33)
Gene therapy (219)
GLP-1 (503)
Government (1455)
Grass and pollen (4)
Guidances (177)
Healthcare (3698)
Hematology (66)
HIV (21)
Huntington's disease (16)
IgA nephropathy (61)
Immunology and inflammation (107)
Immuno-oncology (34)
Indications (109)
Infectious disease (905)
Inflammatory bowel disease (90)
Inflation Reduction Act (7)
Influenza (29)
Intellectual property (150)
Interviews (62)
IPO (5978)
IRA (33)
Job creations (2078)
Job search strategy (390)
JPM (32)
Kidney cancer (15)
Labor market (50)
Layoffs (237)
Leadership (12)
Legal (3464)
Licensing (5)
Liver cancer (27)
Longevity (10)
Lung cancer (257)
Lymphoma (171)
Machine learning (16)
Management (18)
Manufacturing (631)
Marketing (6)
MASH (92)
Medical affairs (1)
Medical device (1322)
Medtech (1344)
Mergers & acquisitions (10145)
Metabolic disorders (589)
mRNA (71)
Multiple sclerosis (66)
NASH (15)
Neurodegenerative disease (133)
Neuropsychiatric disorders (54)
Neuroscience (1161)
Neurotech (1)
NextGen: Class of 2026 (1603)
Non-profit (622)
Now hiring (56)
Obesity (304)
Opinion (158)
Ovarian cancer (69)
Pain (142)
Pancreatic cancer (78)
Parkinson's disease (118)
Partnered (13)
Patents (302)
Patient recruitment (210)
Peanut (15)
People (30586)
Pharmaceutical (34)
Pharmacy benefit managers (19)
Phase 1 (8586)
Phase 2 (13941)
Phase 3 (12623)
Pipeline (3988)
Policy (157)
Postmarket research (1410)
Preclinical (3465)
Press Release (25)
Prostate cancer (122)
Psychedelics (27)
Radiopharmaceuticals (170)
Rare diseases (533)
Real estate (2675)
Recruiting (21)
Regulatory (11674)
Reports (19)
Research institute (588)
Resumes & cover letters (60)
Rett syndrome (12)
RNA editing (9)
RSV (26)
Schizophrenia (92)
Series A (123)
Series B (70)
Service/supplier (1)
Sickle cell disease (62)
Special edition (14)
Spinal muscular atrophy (88)
Sponsored (11)
Startups (1665)
State (2)
Stomach cancer (6)
Supply chain (69)
Tariffs (78)
The Weekly (60)
Vaccines (301)
Venture capital (47)
Weight loss (176)
Women's health (53)
Worklife (4)
Date
Last 7 days (260)
Last 30 days (798)
Last 365 days (10556)
2026 (6565)
2025 (10844)
2024 (12659)
2023 (14454)
2022 (19745)
2021 (20248)
2020 (19135)
2019 (14970)
2018 (11766)
2017 (13968)
2016 (13165)
2015 (15542)
2014 (12466)
2013 (10626)
2012 (11453)
2011 (11988)
2010 (10953)
Location
Africa (327)
Alabama (25)
Alaska (1)
Arizona (94)
Arkansas (4)
Asia (21474)
Australia (2764)
California (4206)
Canada (1882)
China (821)
Colorado (187)
Connecticut (170)
Delaware (177)
Europe (42436)
Florida (795)
Georgia (83)
Hawaii (2)
Idaho (11)
Illinois (496)
India (79)
Indiana (335)
Iowa (2)
Japan (380)
Kansas (87)
Kentucky (21)
Louisiana (7)
Maine (2)
Maryland (531)
Massachusetts (3411)
Michigan (55)
Minnesota (219)
Mississippi (1)
Missouri (41)
Montana (9)
Nebraska (8)
Nevada (19)
New Hampshire (10)
New Jersey (1852)
New Mexico (8)
New York (1197)
North Carolina (776)
North Dakota (2)
Northern California (1990)
Ohio (100)
Oklahoma (5)
Oregon (16)
Pennsylvania (906)
Puerto Rico (18)
Rhode Island (18)
South America (512)
South Carolina (13)
Southern California (1863)
Tennessee (76)
Texas (586)
United States (16572)
Utah (70)
Vermont (1)
Virginia (218)
Washington D.C. (44)
Washington State (308)
West Virginia (1)
Wisconsin (60)
Wyoming (1)
281,127 Results for "takeda pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Takeda’s ‘transformation program’ leaves 4,500 jobless
While Takeda is eliminating 4,500 roles across its global operations, the company has some 2,200 jobs currently open for hiring, for which internal candidates will be prioritized.
May 14, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial
Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.
June 11, 2026
·
1 min read
·
Tristan Manalac
Approvals
Takeda’s narcolepsy nod opens orexin doors
Orzeyful is the first orexin agonist cleared by the FDA, and is the first narcolepsy therapy that addresses the full host of disease symptoms. It is “likely to reshape the treatment paradigm” for the condition, Jefferies told investors.
August 6, 2026
·
2 min read
·
Tristan Manalac
Business
Takeda enters transitional year as new CEO seeks return to growth
For the 2026 fiscal year, Takeda anticipates declines in revenue and profit, highlighting what CEO-elect Julie Kim says is the need for the company to “invest in future growth.”
June 24, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda
In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.
March 31, 2026
·
2 min read
·
Tristan Manalac
Job Trends
May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech
For the second time in 2026, the number of biopharma professionals affected by made or projected workforce reductions rose year over year. In May, layoffs spiked nearly 50%, mainly due to Takeda and BioNTech axing a combined 6,360 employees.
June 11, 2026
·
3 min read
·
Angela Gabriel
Press Releases
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 5, 2026
·
13 min read
Layoffs
Takeda Restructuring Could Push More Than 600 US Staffers Out of Jobs
Takeda’s layoffs include cutting 247 people in Massachusetts. The workforce reduction is meant to help offset investments in areas including a product launch for oral drug candidate zasocitinib, for which the pharma today announced positive Phase 3 data.
March 30, 2026
·
2 min read
·
Angela Gabriel
Neurodegenerative diseases
Takeda Breaks Up With Denali, Dumps Dementia Drug
Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer’s disease, was previously discontinued after an FDA hold and disappointing early data.
April 6, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
July 30, 2026
·
4 min read
1 of 28,113
Next
